OSCR
Oscar Health, Inc.
OSCR has the edge over STLN overall, supported by lower modeled downside and stronger fundamentals.
STLN
Starling Oncology, Inc.
STLN offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
STLN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Stable | |
| Unavailable |
STLN's revenue is currently healthy, and its profitability and cash flow are stable. There isn't enough data to rate its balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
STLN PE Valuation
STLN has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
STLN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect STLN's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over STLN on earnings quality, reporting a profit while its opponent remains loss making.
STLN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.27 | +$0.37 |
| Q2 2026 | -$0.28 | +$0.40 |
| Q1 2026 | -$0.35 | +$0.35 |
| Q4 2025 | -$0.54 | +$0.17 |
| Q3 2025 | -$0.64 | +$0.14 |
| Q2 2025 | -$0.68 | +$0.11 |
| Q1 2025 | -$0.70 | +$0.11 |
| Q4 2024 | -$0.71 | +$0.21 |
STLN is still losing money, but far less than before: $0.27 per share over the past year, against $0.92 at its worst in late 2023.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over STLN on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over STLN on profitability, with a higher operating margin.
STLN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $169.8M | +24% |
| Q2 2026 | $161.3M | +35% |
| Q1 2026 | $147.4M | +41% |
| Q4 2025 | $142M | +42% |
| Q3 2025 | $136.6M | +37% |
| Q2 2025 | $119.8M | +22% |
| Q1 2025 | $104.4M | +10% |
| Q4 2024 | $100.3M | +17% |
STLN's revenue has grown year over year every quarter since early 2023: $170M last quarter, up 24% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1.8% | +4.1 points |
| Q2 2026 | -2.9% | +6.5 points |
| Q1 2026 | -4.4% | +5.1 points |
| Q4 2025 | -4.9% | +7 points |
| Q3 2025 | -5.9% | +8 points |
| Q2 2025 | -9.4% | +7.2 points |
| Q1 2025 | -9.5% | +9.5 points |
| Q4 2024 | -12% | +5.9 points |
STLN's operating margin was −1.8% last quarter, up 4.1 points from the same quarter a year ago, near the top of its range since 2022.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
STLN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.9M | +$22.1M |
| Q2 2026 | $11M | +$22.4M |
| Q1 2026 | -$3.3M | +$2.1M |
| Q4 2025 | $2.2M | -3.2% |
| Q3 2025 | -$13.2M | -1184% |
| Q2 2025 | -$11.4M | +$6.1M |
| Q1 2025 | -$5.3M | +$11.2M |
| Q4 2024 | $2.2M | +$7M |
STLN's free cash flow has turned positive after six years mostly in the red: $19M over the past year.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
STLN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.6% | +1.7M shares |
| 1 year | +7.4% | +7.3M shares |
| 3 years | +43% | +31.3M shares |
| 5 years | +1721% | +99M shares |
STLN has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q4 2023 | — |
| Q3 2023 | $125,000 |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $9M |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
STLN Net Leverage
STLN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
STLN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.7 | Neutral |
| Stochastic | 31.0 | Neutral |
STLN's weekly RSI is 37 (neutral) and its Stochastic is 31 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
STLN PE vs Healthcare Sector
STLN has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over STLN on trend strength, trading above more of its moving averages.
STLN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.83 | 36% below |
| 20 week MA | $5.88 | 36% below |
| 50 week MA | $4.53 | 17% below |
| 100 week MA | $3.49 | 7.4% above |
| 200 week MA | $2.25 | 67% above |
STLN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 67% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over STLN on returns for 2026, with the stronger performance.
STLN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.84 | $10.8 | +9.8% |
| 2021 | $10.8 | $10.4 | -3.3% |
| 2022 | $10.4 | $1.60 | -85% |
| 2023 | $1.60 | $2.04 | +27% |
| 2024 | $2.04 | $0.32 | -84% |
| 2025 | $0.32 | $3.64 | +1038% |
| 2026 YTD | $3.64 | $3.75 | +3% |
STLN's yearly returns have swung widely, from +1038% in 2025 to −85% in 2022. It's up 3% so far in 2026.